

Cover Story
By Matthew Bin Han Ong
A federal judge has ruled against the Health Resources and Services Administration over provider access to 340B Drug Pricing Program discounts for orphan drugs.
By Matthew Bin Han Ong
In Brief


Funding Opportunities
Drugs & Targets


Trending Stories
- NIH Director Jay Bhattacharya launches a podcast
- The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear” - Lou Weisbach tells us about his plan to raise $750 billion for the American Center for Cures
- As Trump decimates NIH funding, a daring proposal to issue $750 billion in bonds for medical cures garners attention
- “Forward funding” NIH budget plan would make competing for grants much harder
- In the Headlines: What if curing diseases was treated like a business?